Literature DB >> 2362191

Perfusion and function at rest and treadmill exercise using technetium-99m-sestamibi: comparison of one- and two-day protocols in normal volunteers.

S Borges-Neto1, R E Coleman, R H Jones.   

Abstract

The purpose of this study was to explore the feasibility of performing rest and exercise technetium-99m-sestamibi (99mTc-sestamibi) studies on the same day. We prospectively studied 34 asymptomatic volunteers using two different protocols (17 patients studied using one-day protocol and 17 patients studied using two-day protocol). For the one-day protocol, the rest study was performed first. For the two-day protocol, the exercise study was performed first followed by a second-day rest study. Left and right ventricular ejection fractions, myocardium/lung, myocardium/liver, myocardium/spleen, and myocardium/gallbladder count ratios were similar for the one- and two-day groups. No significant difference was observed in any variable measured. These data suggest that 99mTc-sestamibi can be used for rest and treadmill exercise studies performed on the same day to provide assessment of ventricular function and perfusion similar to studies performed on separate days.

Entities:  

Mesh:

Year:  1990        PMID: 2362191

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  First-pass radionuclide angiography.

Authors:  John D Friedman; Daniel S Berman; Salvador Borges-Neto; Sean W Hayes; Lynne L Johnson; Kenneth J Nichols; Robert A Pagnanelli; Steven C Port
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 2.  What is the current status of quantification and nuclear medicine in cardiology?

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1996-07

3.  Comparison of technetium-99m sestamibi left ventricular wall motion and perfusion studies with thallium-201 perfusion imaging: in search of the combination of variables with the highest accuracy in predicting coronary artery disease.

Authors:  J F Verzijlbergen; A H Zwinderman; C A Ascoop; E E van der Wall; M G Niemeyer; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1996-05

4.  Simultaneous perfusion/function imaging.

Authors:  D S Berman; G Germano; H Kiat; J Friedman
Journal:  J Nucl Cardiol       Date:  1995 May-Jun       Impact factor: 5.952

5.  Repeatability of treadmill exercise ejection fraction and wall motion using technetium 99m-labeled sestamibi first-pass radionuclide ventriculography.

Authors:  B Benari; H Kiat; J Erel; M Hyun; F P Wang; C Williams; J D Friedman; G Germano; K F Van Train; D Berman
Journal:  J Nucl Cardiol       Date:  1995 Nov-Dec       Impact factor: 5.952

6.  Prediction of severe coronary artery disease by combined rest and exercise radionuclide angiocardiography and tomographic perfusion imaging with technetium 99m-labeled sestamibi: a comparison with clinical and electrocardiographic data.

Authors:  S Borges-Neto; L J Shaw; K L Kesler; M W Hanson; E D Peterson; E I Morris; R E Coleman
Journal:  J Nucl Cardiol       Date:  1997 May-Jun       Impact factor: 5.952

Review 7.  First-pass radionuclide angiocardiography with single-crystal gamma cameras.

Authors:  K Nichols; E G DePuey; A Rozanski
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

8.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

9.  Do patient data ever exceed the partial volume limit in gated SPECT studies?

Authors:  K Nichols; E G DePuey; M I Friedman; A Rozanski
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

10.  Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging.

Authors:  Jamieson M Bourque; Eric J Velazquez; Salvador Borges-Neto; Linda K Shaw; David J Whellan; Christopher M O'connor
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.